Furthermore, we found that patients with tumours with mutations in PIK3CA and/or BRAF tended to exhibit better survival outcomes than those with mutations in TP53, KRAS, and/or EGFR (Fig. 5d and Supplementary Fig. 9). Here, KRAS is linked to neoplasm.